Home

vaccination portefeuille Incliné kras colon cancer treatment canal Eau gazifiée assiette

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal  cancer | Molecular Cancer | Full Text
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer | Molecular Cancer | Full Text

Colorectal Cancer – Treatments | Gastrointestinal Cancer
Colorectal Cancer – Treatments | Gastrointestinal Cancer

Life | Free Full-Text | Integrated Decision-Making in the Treatment of Colon -Rectal Cancer: The Case of KRAS-Mutated Tumors
Life | Free Full-Text | Integrated Decision-Making in the Treatment of Colon -Rectal Cancer: The Case of KRAS-Mutated Tumors

IJMS | Free Full-Text | Gene Therapy Targeting p53 and KRAS for Colorectal  Cancer Treatment: A Myth or the Way Forward?
IJMS | Free Full-Text | Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?

Frontiers | Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS  Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet +  Bevacizumab
Frontiers | Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab

IJMS | Free Full-Text | Prognostic and Predictive Roles of KRAS Mutation in Colorectal  Cancer
IJMS | Free Full-Text | Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer

Promising results for a new bowel cancer treatment
Promising results for a new bowel cancer treatment

JCI Insight - Targeting the undruggable oncogenic KRAS: the dawn of hope
JCI Insight - Targeting the undruggable oncogenic KRAS: the dawn of hope

Chemically modified MIR143-3p exhibited anti-cancer effects by impairing  the KRAS network in colorectal cancer cells: Molecular Therapy - Nucleic  Acids
Chemically modified MIR143-3p exhibited anti-cancer effects by impairing the KRAS network in colorectal cancer cells: Molecular Therapy - Nucleic Acids

Biomedicines | Free Full-Text | Identifying Novel Actionable Targets in Colon  Cancer
Biomedicines | Free Full-Text | Identifying Novel Actionable Targets in Colon Cancer

Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal  cancer. | Semantic Scholar
Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. | Semantic Scholar

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of  cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal  cancer: a retrospective consortium analysis - The Lancet Oncology
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis - The Lancet Oncology

Study reveals potential target for precision colorectal cancer treatment -  Redox Medicine Society
Study reveals potential target for precision colorectal cancer treatment - Redox Medicine Society

Comprehensive characterization of RAS mutations in colon and rectal cancers  in old and young patients | Nature Communications
Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients | Nature Communications

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations  in patients with primary and metastatic colorectal cancer
Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer

The current treatment paradigm for patients with metastatic colorectal... |  Download Scientific Diagram
The current treatment paradigm for patients with metastatic colorectal... | Download Scientific Diagram

The current understanding on the impact of KRAS on colorectal cancer -  ScienceDirect
The current understanding on the impact of KRAS on colorectal cancer - ScienceDirect

Tumor microenvironment-adjusted prognostic implications of the KRAS  mutation subtype in patients with stage III colorectal cancer treated with  adjuvant FOLFOX | Scientific Reports
Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX | Scientific Reports

RAS mutations: impact on treatment outcome | Colorectal Cancer
RAS mutations: impact on treatment outcome | Colorectal Cancer

Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer:  Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer  Database in: Journal of the National Comprehensive Cancer Network Volume 19  Issue 3 (2021)
Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database in: Journal of the National Comprehensive Cancer Network Volume 19 Issue 3 (2021)

Frontiers | Targeting KRAS: The Elephant in the Room of Epithelial Cancers
Frontiers | Targeting KRAS: The Elephant in the Room of Epithelial Cancers

Identification of actionable alterations in colorectal cancer are leading  to the development of novel treatment strategies - Mayo Clinic
Identification of actionable alterations in colorectal cancer are leading to the development of novel treatment strategies - Mayo Clinic

KRAS mutation: from undruggable to druggable in cancer | Signal  Transduction and Targeted Therapy
KRAS mutation: from undruggable to druggable in cancer | Signal Transduction and Targeted Therapy

Colorectal Cancer
Colorectal Cancer

Target Genetic Abnormalities for the Treatment of Colon Cancer and Its  Progression to Metastasis | Bentham Science
Target Genetic Abnormalities for the Treatment of Colon Cancer and Its Progression to Metastasis | Bentham Science